Safety Of Intravenous Iron Sucrose Research Articles

The response of Intravenous Iron sucrose in children with Iron Deficiency Anaemia unresponsive to Oral Iron Therapy.

Objective: To evaluates the efficacy and safety of intravenous iron sucrose in paediatric patients with IDA who have not responded to or tolerated oral iron therapy.Methodology: This observational study was conducted at Department of Paediatrics, Pakistan aeronautical complex (PAC) Hospital Kamra, from October 2023 to April 2024. Iron sucrose (Venofer®) was administered at a dose of 0.35 ml/kg, providing 100 to 200 mg of elemental iron per dose, on alternate days for three doses. Haemoglobin (Hb) and serum ferritin levels were measured 4 weeks post-treatment to evaluate response.Results: Among the participants, 70 (70%) were male and 30 (30%) were female, with a mean age of 34.23 ±19.54 months. Results showed a significant increase in mean Hb from 7.92 ± 0.74 g/dl before treatment to 10.46 ± 0.94 g/dl after treatment (p = 0.001)Conclusion: Clinicians should consider intravenous iron therapy to enhance patient outcomes, improve quality of life, and potentially reduce healthcare costs. Keywords: Iron Deficiency Anaemia (IDA), Anaemia, Haemoglobin (Hb), Oral Iron, Intravenous Iron.

Intravenous iron sucrose in postnatal iron deficiency anaemia: A safe option

Introduction: Iron deficiency anaemia is the most common type of reversible anemia encountered during postpartum period and may lead to long-standing iron deficiency. If treated, it facilitates a healthy future for mother and children. Aims and Objectives: To know safety of intravenous iron sucrose in treatment of postpartum iron deficiency anaemia. Materials and Methods: 91 postnatal women with iron deficiency anaemia with haemoglobin between 7-10g/dl were included prospectively at IGGMCH Nagpur. These women were given 200 mg of elemental iron infused over 30 minutes every alternate day until the required dosage is infused. The blood samples of all the patients were collected and analyzed for Hb and other RBC indices before and after therapy. Result: Majority of the patients were multi-para (63.76%) belonging to lower socio-economic groups. All blood parameters were increased significantly when compared from baseline values. Mean raise in Hb, hematocrit, MCV, MCH, MCHC and serum ferritin are 1.3, 2.3, 3.4fL, 2.3pg, 3.5 gm/dl and 53.71mcg/l respectively after 30 days of treatment. Conclusion: Intravenous iron sucrose was very well tolerated and safe for treating postnatal iron deficiency anaemia.

Efficacy and safety of intravenous iron sucrose in children younger than 2 years with intestinal failure.

Iron-deficiency anemia (IDA) is highly prevalent in children with intestinal failure (IF) and oral iron supplementation is often ineffective in this patient population. Even though various intravenous (IV) iron formulations are available, there is a dearth of data on the use of newer parenteral iron products such as IV iron sucrose, especially in infants and young children (<2 years of age) with IF. To determine safety and efficacy, we performed a retrospective chart review on infants and children younger than 2 years with IF who received IV iron sucrose for IDA between October 2019 and August 2021. The review revealed that 10 events of IV iron sucrose replacement were administered to five children aged 4-22 months with IF and IDA. We observed a mean increase in hemoglobin of 1.9 ± 0.6 g/dl, and peak hemoglobin levels were seen at 4.3 ± 0.8 weeks after the IV iron sucrose dose. The infusions were well tolerated, and no short-term adverse reactions or laboratory abnormalities were observed. Based on these observations, the use of IV iron sucrose appears to be safe and effective in infants and young children with IF and could be considered in the management of IDA in this patient population.

Efficacy and safety of intravenous iron sucrose for treatment of iron deficiency anemia in pregnancy

&lt;p class="abstract"&gt;&lt;strong&gt;Background: &lt;/strong&gt;Leading cause of anemia is due to thedeficiency of iron in pregnant women. The aim of the study was to evaluate the efficacy of intravenous iron sucrose for the treatment of iron deficiency anemia in pregnancy particularly for those who had unsatisfactory response to oral iron therapy.&lt;/p&gt;&lt;p class="abstract"&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is an open label, observational study that was carried out in Jamal Noor Hospital, Karachi for 6 months by using non-probability consecutive sampling technique, after taking ethical approval. Seventy two pregnant women with level of Hb equivalent to or &amp;lt;10 g/dl, Serum ferritin level equivalent to or &amp;lt;10 μg/l with the age ranging from 18-40 years, Gestational age 16 weeks or above were included in the study. A two times-weekly dose of 200 mg of iron sucrose (Axifer) intravenously were infused to pregnant women. However, the dose was calculated for every patient through total iron deficit. SPSS version 22 was used to analyze the data.&lt;/p&gt;&lt;p class="abstract"&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study results showed that the mean age of the pregnant womenwas 25.83±5.03 years, their mean weight was 59.50±10.28 kg, and their mean gestational week was 28.88±4.09. It showed that both the haemoglobin (9.01±0.74 mg/dl versus 11.92±11.07 mg/dl), (p&amp;lt;0.001) and ferritin levels (9.85±12.38 ng/ml versus 50.74±59.42 ng/ml), (p&amp;lt;0.001)were significantly increased at term after receiving intravenous iron sucrose as compared to the baseline.&lt;/p&gt;&lt;p class="abstract"&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; This study concluded that the administration of iron sucrose (Axifer) intravenously is a secure and effective choice in the management of iron deficiency anemia in pregnant women particularly for those who had inadequate response to oral iron supplementation.&lt;/p&gt;

Efficacy, tolerability and safety of intravenous iron sucrose in postpartum anaemia

Background: Anemia is one of major contributing factor in maternal mortality and morbidity in third world countries and according to the WHO, contributes to 40% maternal deaths. Postpartum anemia is observed in up to 27% of women.It is a common problem throughout the world. Treatment of postpartum iron deficiency anemia includes oral and parenteral iron supplmentaion as well as blood transfusion in severe cases. Methods: This was a prospective longitudinal study carried out in Department of Obstetrics &amp; Gynaecology of PRH, Loni. Total 80 women suffering from postpartum anemia of age above 18 years with haemoglobin (HB) level below 11gm/dl and above 6gm/dl were included for the study. After history taking, clinical examination and baseline Hb level, all of them were administered intravenous iron sucrose 200 mg per dose per day till the total calculated dose was administered. The post therapy evaluation was done with the estimation of Hb on day 1, day 7, day 14 and day 21. Results: 31.25% women belonged to the age group each of 19-21 years and 22-24 years. Maximum number of patients received 3 doses of IV Iron sucrose (i.e. total 600mg) followed by 2 doses (i.e. total 400mg), 4 doses (i.e. total 800mg) and 5 doses (i.e. total 1000mg) respectively. Hb level rises extremely significantly (p&lt;0.001) after IV Iron Sucrose administration on day 1, 7, 14 &amp; 21 as compared to corresponding values before delivery as analyzed by Friedman Test (Nonparametric Repeated Measures ANOVA) . 16 patients (20%) experienced thrombophlebitis to IV Iron Sucrose administration. About 12 (15%) patients experienced rigor followed by sweating in 10 patients (12.5%) and fever in 8 patients (10%). About 62 patients (77.5%) from total 80 reported well tolerability to IV Iron Sucrose while remaining 18 patients (22.5%) reported poor tolerability to IV Iron Sucrose Conclusion: Intravenous iron sucrose increases the haemoglobin more rapidly in first week as compared to second and third week in women with postpartum iron deficiency anemia. Hypersensitivity reaction, chest pain, dyspnoea reported with iron dextran and iron sorbitol citric acid were not observed with iron sucrose. Intravenous iron sucrose can be used safely to fill a rift between blood transfusion and oral iron in treatment of postpartum iron deficiency anemia.

Comparison of efficacy and safety of intravenous iron sucrose and intramuscular iron sorbitol therapy in patients with anemia during pregnancy in a developing country

Background: Iron deficiency anemia due to poor nutritionis estimated to affect nearly two thirds ofall pregnant women in developing countriesparticularly in India. The responsible constellation of factors producing iron deficiency anemia generally precede the pregnancy, which includedeficient diet in iron content coupled with menstrual losses,generally a rapid succession of pregnancies and inadequate supplemental iron are a few to be blamed for a high incidence of anemia in such population.Aims and Objectives: To compare the efficacy and safety of iron sucrose versus iron sorbitol therapy in pregnant anemic patients.Material and Methods: Two-hundred antenatal women attending the out patient department having hemoglobin levels of 8 gm% or less were recruited in the study and were randomized into two groups for receiving intravenous and intramuscular iron therapy.Results and Conclusions: There was a significant improvement in the haematologicalparameters and no major side effects developed in the intravenous iron sucrose group.Though there was a significant improvement in the haematological parameters after intramuscular iron sorbitol therapy also butnone of the cases reached the target level of haemoglobinduring the observation period.Asian Journal of Medical Sciences Vol.8(5) 2017 31-35

A study of efficacy and safety of intravenous iron sucrose for the treatment of moderate anaemia in antenatal women in South India

Background: Iron deficiency anaemia in pregnancy is a common medical problem throughout India with the burden of disease impacting on both mother and the newborn. The WHO technical group working on the prevention and treatment of anaemia has documented that parenteral iron therapy has produced a rapid and better correction of iron deficiency anaemia.Methods: A total of 61 antenatal women in the age group of 18-25yrs were enrolled and randomly assigned into study group. For a period of 4 weeks, study group received iron sucrose intravenously. The results were noted, tabulated, analysed and expressed as descriptive statistics. Student's ‘t’ test and percentages were compared using chi square test. P -value, &lt;0.001 was considered significant. The results were analysed by using SPSS V-21 software.Results: Mean rise of Hb was 2.51±0.44 with IV iron sucrose this was highly significant (HS). Mean rise of MCV was 8.02±6.72 with IV iron sucrose this was not significant (NS). Mean rise of PCV was5.7±2.77 with IV iron sucrose. These findings showed improvement in Hb and PCV which were statistically highly significant (HS). Adverse effects were 14% in the group.Conclusions: The present study proved that iron sucrose when given intravenously there was a rapid improvement in anaemia. IV iron sucrose was proved to be safe with minimal side effects.

Intravenous iron sucrose and oral iron for the treatment of iron deficiency anaemia in pregnancy.

The aim of this study was to compare the efficacy and safety of intravenous iron sucrose and oral iron administration for the treatment of iron deficiency anaemia in pregnancy. Hundred women with gestational age between 30 and 34 weeks with established iron deficiency anaemia with Haemoglobin-6-8g/dL were randomised to receive either oral ferrous sulphate 200 mg thrice daily or required dose of intravenous iron sucrose 200 mg in 200 ml NS on alternate days. Haemoglobin, haematocrit, mean corpuscular volume, reticulocyte count were measured at recruitment and on 2(nd) week, 4(th) week and at 37 weeks. Adverse drug reactions were also noted in both the groups. RESULTS were analyzed by student's t-test and Chi-square test. Haemoglobin values varied significantly with time between the two groups at second week, 4(th) week and at term (p<0.005). The mean difference in mean corpuscular volume from the recruitment value was not significant at 2(nd) week. When compared to iron sucrose group, oral iron group had significant gastro-intestinal adverse effects. Intravenous iron sucrose treated iron deficiency anaemia of pregnancy faster, and more effectively than oral iron therapy, with no serious adverse drug reactions.

A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy.

The aim of this study was to compare the efficacy and safety of intravenous iron sucrose with oral iron therapy in pregnant patients with anemia. The primary outcome of the study was increase in haemoglobin on day 7, 14 & 28 and rise of serum ferritin over 28 days. The study population consisted of 100 patients with singleton pregnancy between 24 and 34 weeks, hemoglobin levels between 7.0-9.0gm/dL and serum ferritin levels less than 15ng/mL. The participants in the oral group were given daily 180mg elemental iron in three divided oral doses for 4 weeks. Total calculated dose of iron sucrose with a target hemoglobin of 11gm%, was given in 200 mg dose on alternate days. Mean haemoglobin rise was 0.58gm/dL in the IV group as compared to 0.23gm/dL in the oral group on day 14 and 1.9gm/dL in the IV group & 1.3gm/dL in the oral group on day 28, (p <0.05). In the IV group, 76% of the subjects achieved haemoglobin levels of ≥11gm% at the time of delivery, as compared to only 54% of the subjects in the oral group who achieved these levels. Serum ferritin value was significantly higher in the IV group, 37.45 ± 5.73 ng/mL as compared to 13.96 ± 1.88 ng/mL in the oral group at 4th week (p <0.001). There was no major side effect in the IV group. 36% subjects in the oral group developed gastrointestinal side effects & 10% of the subjects were non compliant. The rate of hemoglobin rise is faster with intravenous iron sucrose therapy as compared to oral iron therapy which can be beneficial in pregnant women presenting with anemia at a later period of gestation. Intravenous iron sucrose is very well tolerated during pregnancy.

Comparative study on efficacy &amp; safety of intravenous iron sucrose versus intramuscular iron sorbitol therapy in anemia during pregnancy

Aims and Objectives: To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron Sorbitol therapy for anemia during pregnancy. Material and Methods: 100 antenatal cases of gestational age 16-32 weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50cases in group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. Results: The mean pretherapy hemoglobin in group A was 6.49 g/dl and in group B was 6.48 g/dl. The rise in hemoglobin after 4 weeks of starting therapy was 3.52 g/dl in group A and 2.33 g/dl in group B The difference was Statistically significant (P 11 g/dl) was 6.37 weeks in group A and 9.04 weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups no case discontinued the therapy. Conclusion: Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.

A Study to Compare the Efficacy and Safety of Intravenous Iron Sucrose and Intramuscular Iron Sorbitol Therapy for Anemia During Pregnancy

To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron sorbitol therapy for anemia during pregnancy. 100 antenatal cases of gestational age 14-32weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50 cases in Group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. The mean pretherapy hemoglobin in group A was 6.49gm/dl and in group B was 6.48gm/dl. The rise in hemoglobin after 4weeks of starting therapy was 3.52gm/dl in group A and 2.33gm/dl in group B. The difference was statistically significant (P<0.01). The mean time taken to achieve target hemoglobin (≥11gm/dl) was 6.37weeks in group A and 9.04weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups, no case discontinued the therapy. Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.

Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia

BackgroundIron deficiency is the most common disorder in the world, affecting approximately 25% of the world`s population and the most common cause of anemia.ObjectiveTo evaluate the efficacy and safety of intravenous iron sucrose (IS) in the treatment of adults with iron deficiency anemiaMethodsEighty-six adult patients with iron deficiency anemia, who had intolerance or showed no effect with oral iron therapy, received a weekly dose of 200 mg of intravenous iron sucrose until the hemoglobin level was corrected or until receiving the total dose of intravenous iron calculated for each patientResultsThe mean hemoglobin and serum ferritin levels were 8.54 g/dL and 7.63 ng/mL (pre-treatment) and 12.1 g/dL and 99.0 ng/mL (post-treatment) (p-value < 0.0001), respectively. The average increases in hemoglobin levels were 3.29 g/dL for women and 4.58 g/dL for men; 94% of male and 84% of female patients responded (hemoglobin increased by at least 2 g/dL) to intravenous iron therapy. Correction of anemia was obtained in 47 of 69 (68.1%) female patients and in 12 of 17 male (70.6%) patients. A total of 515 intravenous infusions of iron sucrose were administered and iron sucrose was generally well tolerated with no moderate or serious adverse drug reactions recorded by the investigators.ConclusionsOur data confirm that the use of intravenous iron sucrose is a safe and effective option in the treatment of adult patients with iron deficiency anemia who lack satisfactory response to oral iron therapy. Intravenous iron sucrose is well tolerated and with a clinically manageable safety profile when using appropriate dosing and monitoring. The availability of intravenous iron sucrose would potentially improve compliance and thereby reduce morbidities from iron deficiency.

Intravenous Iron Sucrose versus Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease-A Randomized, Controlled, Open-Label, Multicenter Study

Anemia is a frequent complication in patients with inflammatory bowel disease (IBD). The optimal route for iron supplementation to replenish iron stores has not been determined so far. We therefore evaluated the efficacy and safety of intravenous iron sucrose as compared with oral iron sulfate for the treatment of iron deficiency anemia (IDA) in patients with IBD. A randomized, prospective, open-label, multicenter study was performed in 46 patients with anemia and transferrin saturation <or=20% and/or serum ferritin concentrations <or=20 microg/L. The intravenous group received a single dose of iron sucrose of 7 mg iron/kg body weight, followed by five 200 mg infusions for the following 5 wks. The oral group received iron sulfate 100-200 mg per day for 6 wks. While a comparable increase in hemoglobin was observed for both administration routes (median increase 0.25 g/L in the intravenous group vs 0.21 g/L in the oral group), only iron sucrose led to a rise in serum ferritin concentrations. Intractable gastrointestinal adverse events caused permanent study drug discontinuation in five patients (20.8%) receiving iron sulfate, whereas only one patient (4.5%) had to be withdrawn because of side effects due to iron sucrose. Although being equal in short-term efficacy and overall tolerability our results suggest a better gastrointestinal tolerability for iron sucrose. Larger trials are mandatory to prove a possible advantage of iron sucrose in short- and long-term efficacy as well as in tolerability over iron sulfate in the management of IDA in IBD.